Belgian radiopharmaceutical firm Ion Beam Applications (IBA) has completed development of a pencil-beam scanning (PBS) module for its proton beam therapy system.
The Louvain-la-Neuve company said it would be filing for U.S. Food and Drug Administration (FDA) clearance for the PBS module. When approved, PBS will be one of four treatment modes available on the company's IBA universal nozzle proton therapy product. The other modes include single scattering, double scattering, and uniform scattering.
Copyright © 2008 AuntMinnie.com